Pacira (PCRX) Q2 Revenue Rises 1.7%

Pacira BioSciences (NASDAQ:PCRX) is a specialty pharmaceutical company known for its non-opioid pain management products. On August 5, 2025, it reported financial results for the quarter. The headline results showed non-GAAP earnings per share of $0.74, beating analyst consensus by 4.2% (non-GAAP), while revenue (GAAP) came in at $181.1 million, missing GAAP revenue expectations by 1.1%. Compared to a year ago, GAAP revenue rose 1.7%, with modest growth in the flagship EXPAREL product and slight gains for ZILRETTA net product sales. The quarter saw higher operating expenses (GAAP) and a narrowed revenue guidance range for the year. Overall performance reflected progress in manufacturing and innovation, but top-line growth (GAAP revenue) remained subdued. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Pacira BioSciences develops and markets non-opioid pain products for surgical and musculoskeletal conditions. Its key offerings include EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain; ZILRETTA, an injectable extended-release steroid for osteoarthritis knee pain; and iovera°, a device for nerve block treatments. EXPAREL accounts for most of Pacira’s revenue, making its continued adoption essential for the company’s results.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool